JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: One patient with two distinct myeloproliferative disorders

Leukemia

Volumn 22, Issue 7, 2008, Pages 1454-1455

  Cambier, N ^a,b   Renneville, A ^c   Cazaentre, T ^a,b   Soenen, V ^c   Cossement, C ^c   Giraudier, S ^d   Grardel, N ^c   Lai J L ^c   Rose, C ^a,b   Preudhomme, C ^b,c  

^a Hôpital Saint Vincent   (France)

^b Institut de Recherche sur le Cancer de Lille   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; GENOMIC DNA; IMATINIB; JANUS KINASE; PHENYLALANINE; VALINE;

ADULT; CASE REPORT; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; DRUG RESPONSE; DRUG TOLERABILITY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE MUTATION; GENE REARRANGEMENT; HOMOZYGOSITY; HUMAN; HUMAN CELL; LETTER; LEUKEMIA REMISSION; LEUKOCYTE; LEUKOCYTOSIS; MALE; MINIMAL RESIDUAL DISEASE; PHILADELPHIA CHROMOSOME POSITIVE CELL; PHLEBOTOMY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PRURITUS; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SPLENOMEGALY;

FUSION PROTEINS, BCR-ABL; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MUTATION; PIPERAZINES; POLYCYTHEMIA VERA; PYRIMIDINES;

EID: 47549090473     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2405088     Document Type: Letter

References (11)

1. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature 2005; 434: 1144-1148.
2. Inami M, Yamaguchi H, Hasegawa S, Mitamura Y, Kosaka F, Kobayashi A et al. Analysis of the exon 12 and 14 mutations of the JAK2 gene in Philadelphia chromosome-positive leukemia. Leukemia 2007; e-pub ahead of print, 13 September 2007 (doi:10.1038/si.leu.2404953).
3. Haq AU. Transformation of polycythemia vera to Ph-positive chronic myelogenous leukemia. Am J Hematol 1990; 35: 110-113.
4. Hussein K, Bock O, Seegers A, Flasshove M, Henneke F, Buesche G et al Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood 2007; 109: 4106-4107.
5. Inami M, Inokuchi K, Okabe M, Kosaka F, Mitamura Y, Yamaguchi H et al Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia. Leukemia 2007; 21 1103-1104.
6. Bornhäuser M, Mohr B, Oelschlaegel U, Bornhäuser P, Jacki S, Ehninger G et al. Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis. Leukemia 2007; 21: 1824-1826.
7. James C, Delhommeau F, Marzac C, Teyssandier I, Le Couedic JP, Giraudier S et al. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia 2006; 20: 350-353.
8. Wahlin A, Golovleva I. Emergence of Philadelphia positive chronic myeloid leukaemia during treatment with hydroxyurea for Philadelphia negative essential thrombocythaemia. Eur J Haematol 2003; 70 240-241.
9. Kohno T, Amenomori T, Atogami S, Sasagawa I, Nakamura H, Kuriyama K et al. Progression from myelodysplastic syndrome to acute lymphoblastic leukaemia with Philadelphia chromosome and p190 BCR-ABL transcript. Br J Haematol 1996; 93: 389-391.
10. Roumier C, Daudignon A, Soenen V, Dupriez B, Wetterwald M, Lai JL et al. p190 bcr-abl rearrangement: A socondary cytogenetic event in some chronic myeloid disorders? Haematologica 1999; 84: 1075-1080.
11. Gaikwad A, Nussenzveig R, Liu E, Gottshalk S, Chang K, Prchal JT. In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele. Exp Hematol 2007; 35: 587-595.